Biotechnology
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline
TransCode Therapeutics has acquired Polynoma and secured $25 million from CK Life Sciences to advance its Phase 2 trial of TTX-MC138 and Phase 3-ready melanoma vaccine seviprotimut-L, positioning the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
Ocumetics Reports Promising Early Results for Vision-Restoring Lens Technology
Ocumetics Technology Corp. has reported encouraging one-month postoperative results for its accommodating intraocular lens, showing potential to restore natural vision across distances without glasses.
ABVC BioPharma Receives $566,000 in Cumulative Payments Under Vitargus Licensing Agreement
ABVC BioPharma has received cumulative payments of $566,000 from ForSeeCon Eye Corporation under their Vitargus licensing agreement, with the funds supporting GMP facility preparation for the biodegradable vitreous substitute's production.
Quantum BioPharma Pioneers Digitally Integrated Biotech Model with Neuroprotective MS Treatment
Quantum BioPharma is transforming biotechnology through a digitally engineered approach that combines clinical innovation with consumer health commercialization and modern market infrastructure.
Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
Oragenics Inc. has formed a strategic collaboration with Receptor.AI to leverage artificial intelligence for developing neurological therapeutics, marking a significant expansion beyond its concussion treatment program.
Quantum BioPharma Advances Multiple Sclerosis Treatment Toward Clinical Trials
Quantum BioPharma has received final toxicity reports for its Lucid-MS drug candidate, clearing a critical regulatory hurdle toward Phase 2 clinical trials for treating multiple sclerosis by targeting demyelination.
Nightmare Bacteria Infections Surge in U.S., Prompting Urgent Response from Biotech Sector
The rapid spread of antibiotic-resistant 'nightmare bacteria' in the United States is driving increased focus on biotech companies developing novel treatments to address this growing public health crisis.
Lantern Pharma's AI Platform Helps Hoth Therapeutics Accelerate Drug Development
Hoth Therapeutics is using Lantern Pharma's PredictBBB.ai platform to streamline drug candidate selection by predicting blood-brain barrier penetration with 94% accuracy, potentially accelerating development of neurological treatments.
Soligenix Secures $7.5 Million Financing to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, providing critical funding to advance multiple late-stage rare disease treatments including its cutaneous T-cell lymphoma therapy HyBryte™.
GeoVax Sponsors 2025 Global Health Equity Summit to Advance Vaccine Access
GeoVax's sponsorship of the Dr. David Satcher Global Health Equity Summit highlights the biotechnology company's commitment to ensuring equitable global access to vaccines and therapies, particularly for immunocompromised and underserved populations.
Soligenix Expands European Medical Advisory Board to Advance Cutaneous T-Cell Lymphoma Treatment
Soligenix Inc. has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma, strengthening European engagement ahead of potential commercialization of this novel photodynamic therapy.
Scorpion Venom Compound Shows Promise in Brain Cancer Treatment Research
Researchers are exploring how scorpion venom compounds could revolutionize brain tumor treatment by helping the immune system target glioblastoma more effectively.
GeoVax Labs Secures $2.5 Million in Registered Direct Offering to Advance Clinical Programs
GeoVax Labs has raised $2.5 million through a registered direct offering to fund clinical development of its COVID-19 vaccine candidates and oncology therapies, positioning the company to advance multiple late-stage clinical trials.
Lexaria Bioscience Secures $4 Million in Capital to Advance 2026 Research and Development Initiatives
Lexaria Bioscience Corp. has completed a $4 million registered direct offering, providing crucial funding to advance its 2026 R&D and business development plans for its DehydraTECH drug delivery technology.
Quantum BioPharma Shareholders Approve Corporate Direction at Annual Meeting
Quantum BioPharma Ltd. secured full shareholder support for its strategic direction during its annual general meeting, highlighting investor confidence in the company's neurodegenerative and metabolic disorder treatments.
VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services
VolitionRx has entered a co-marketing agreement with Hologic to promote its Nu.Q® Discover epigenetic profiling service, expanding access to pharmaceutical and academic researchers in a market valued at $200 million annually.
Tevard Biosciences Demonstrates Breakthrough Protein Restoration in Genetic Muscle and Heart Diseases
Tevard Biosciences presented preclinical data showing its tRNA-based therapy can restore 70% of functional proteins in Duchenne muscular dystrophy and dilated cardiomyopathy models, potentially enabling clinical advancement for genetic diseases affecting millions worldwide.
Lexaria Bioscience Secures $4 Million in Capital Through Registered Direct Offering
Lexaria Bioscience Corp. has raised $4 million through a registered direct offering, providing crucial working capital to advance its DehydraTECH drug delivery platform technology.
Clene's CNM-Au8 Shows Promising Brain Energy Improvements in Multiple Sclerosis Patients
Clene Inc. presented positive trial results demonstrating that its investigational therapy CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients, potentially offering a new approach to slowing disease progression by addressing underlying bioenergetic failure.
Lionheart Health to Showcase Regenerative Technology at Prestigious Medical Innovation Forum
Lionheart Health's upcoming presentation at the Octane Medical Innovation Forum highlights the company's groundbreaking work in organ regeneration and healthspan longevity technologies, signaling significant advancements in the medical aesthetics and aging management industries.
Quantumzyme Corp. Secures Patent for Sustainable Ibuprofen Manufacturing Process
Quantumzyme Corp. has achieved a significant milestone with the USPTO publication of its patent for an enzymatic ibuprofen synthesis method, representing a major advancement in sustainable pharmaceutical manufacturing.
Creative Biolabs Launches Advanced Antibody Tools for Neuroscience Research
Creative Biolabs has developed specialized antibody products targeting key neurological proteins that could accelerate research into neurodegenerative diseases, movement disorders, and synaptic function.
BB Biotech Gains Inclusion in SIX Swiss Exchange's SPI ESG Index
BB Biotech AG's inclusion in the SPI ESG Index validates its sustainable investment approach and enhances its appeal to ESG-focused investors in the biotechnology sector.
Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. has obtained FDA approval for a Type C meeting regarding its AVERSA™ abuse-deterrent fentanyl patch technology, marking a significant regulatory milestone in addressing opioid abuse through transdermal pharmaceutical innovation.
Creative Biolabs Expands IVD Capabilities with Integrated Protein and Nucleic Acid Detection
Creative Biolabs has enhanced its in vitro diagnostics services by integrating protein and nucleic acid detection technologies, offering researchers more comprehensive biomarker analysis for early disease detection and complex condition research.
Creative Biolabs Accelerates CAR-T Therapy Innovation with Advanced Development Platform
Creative Biolabs is enhancing CAR-T therapy research through its comprehensive development platform, offering specialized viral vectors and ready-made plasmids that address critical challenges in scalability, cost, and technical efficiency for both blood cancers and emerging solid tumor applications.
Viromed Medical AG Achieves ISO 13485 Certification, Clears Path for ViroCAP® Market Launch
Viromed Medical AG's ISO 13485 certification enables independent market entry for its ViroCAP® cold plasma medical devices, positioning the company for accelerated growth in dermatology and veterinary markets starting October 2025.
Plus Therapeutics Subsidiary CNSide Diagnostics Achieves CLIA Accreditation for CNS Cancer Testing Lab
CNSide Diagnostics has received CMS accreditation for its clinical laboratory, enabling broader patient access and insurance coverage for its cerebrospinal fluid assay platform used in central nervous system cancer detection.
Oncotelic Therapeutics Advances Cancer Research with AI and Nanomedicine Pipeline
Oncotelic Therapeutics is leveraging artificial intelligence and nanomedicine to develop innovative treatments for aggressive cancers and rare pediatric diseases, backed by a substantial intellectual property portfolio.